Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An ...

City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today ...

Genolution has completed a PCT international application for an RNA interference (RNAi)-based crop protection composition ...

Alnylam Pharmaceuticals, Inc. ALNY stock is up on Thursday after the company announced a strategic collaboration with ...

By John Vandermosten, CFA NASDAQ: RNAZ READ THE FULL RNAZ RESEARCH NOTE RNA Oncology Ribonucleic acid (RNA) oncology is a specialized field in the cancer space that focuses on using RNA-based ...

Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics has landed a nearly $100 million series B to fund a clinical push and power further development of its ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

US biotech City Therapeutics has raised $99.5 million in a series B financing, giving the young RNA interference specialist ...

Want Diversified Upside in Biotechnology? Check out LABU Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...